American Journal of Kidney Diseases
Volume 51, Issue 6 , Pages 904-913 , June 2008

Effect of Fenofibrate on Kidney Function: A 6-Week Randomized Crossover Trial in Healthy People

  • Jean-Claude Ansquer, MD

      Affiliations

    • Laboratoires Fournier, Daix, France
    • ,
  • R. Neil Dalton, PhD

      Affiliations

    • WellChild Laboratory, Evelina Children's Hospital, St Thomas' Hospital, London, UK
    • ,
  • Elisabeth Caussé, MD

      Affiliations

    • Biochimie, Centre Hospitalier Universitaire Rangueil, Toulouse, France.
    • ,
  • Dominique Crimet, MD

      Affiliations

    • Laboratoires Fournier, Daix, France
    • ,
  • Karine Le Malicot, MS

      Affiliations

    • Laboratoires Fournier, Daix, France
    • ,
  • Christelle Foucher, PhD

      Affiliations

    • Laboratoires Fournier, Daix, France
    • Corresponding Author InformationAddress correspondence to Christelle Foucher, PhD, Laboratoires Fournier, Clinical Research and Medical Affairs Department, 50 Rue de Dijon, 21121 Daix, France.

Received 26 July 2007 ,Accepted 28 January 2008.

References 

  1. Hottelart C, El Esper N, Achard J-M, Pruna A, Fournier A. Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency [French]. Nephrologie. 1999;20:41–44
  2. Ritter JL, Nabulsi S. Fenofibrate-induced elevation in serum creatinine. Pharmacotherapy. 2001;21:1145–1149
  3. Hottelart C, El Esper N, Rose F, Achard J-M, Fournier A. Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron. 2002;92:536–541
  4. Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard C. Comparative effects of cerivastatin and fenofibrate on the atherogenic lipoprotein phenotype in proteinuric renal disease. J Am Soc Nephrol. 2001;12:341–348
  5. Broeders N, Knoop C, Antoine M, Tielemans C, Abramowicz D. Fibrate-induced increase in blood urea and creatinine: Is gemfibrozil the only innocuous agent?. Nephrol Dial Transplant. 2000;15:1993–1999
  6. Devuyst O, Goffin E, Pirson Y, Van Ypersele de Strihou CH. Creatinine rise after fibrate therapy in renal graft recipients. Lancet. 1993;341:840
  7. De Lorgeril M, Boissonnat P, Bizollon CA, et al. Pharmacokinetics of cyclosporine in hyperlipidemic long-term survivors of heart transplantation. Eur J Clin Pharmacol. 1992;43:161–165
  8. Boissonnat P, Salen P, Guidollet J, et al. The long-term effects of the lipid-lowering agent fenofibrate in hyperlipidemic heart transplant recipients. Transplantation. 1994;58:245–247
  9. Lipscombe J, Lewis GF, Cattran D, Bargman JM. Deterioration in renal function associated with fibrate therapy. Clin Nephrol. 2001;55:39–44
  10. Gajdos M, Dzurik R. Fibrates and renal function. Clin Nephrol. 2003;60:65–66
  11. Angeles C, Lane BP, Miller FM, Nord EP. Fenofibrate-associated reversible acute allograft dysfunction in 3 renal transplant recipients: Biopsy evidence of tubular toxicity. Am J Kidney Dis. 2004;44:543–550
  12. Levin A, Duncan L, Djurdjev O, et al. A randomized placebo-controlled double-blind trial of lipid-lowering strategies in patients with renal insufficiency: Diet modification with or without fenofibrate. Clin Nephrol. 2000;53:140–146
  13. Ansquer J-C, Foucher C, Rattier S, Taskinen M-R, Steiner G DAIS Investigators. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis. 2005;45:485–493
  14. The FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (The FIELD Study): Randomised controlled trial. Lancet. 2005;366:1849–1861
  15. Masson P, Ohlsson P, Bjorkhem I. Combined enzymic-Jaffé method for determination of creatinine in serum. Clin Chem. 1981;27:18–21
  16. Lamb EJ, Vickery S, Dalton RN, Stevens PE. Estimating GFR with ID-MS traceable creatinine assays. Ann Clin Biochem. 2006;43:327
  17. Toto RD. Conventional measurement of renal function utilizing serum creatinine, creatinine clearance, inulin and para-aminohippuric acid clearance. Curr Opin Nephrol Hypertens. 1995;4:505–509
  18. Shannon JA, Smith HW. The excretion of inulin, xylose and urea by normal and phlorizinized man. J Clin Invest. 1935;14:393–401
  19. Walser M, Davidson DG, Orloff J. The renal clearance of alkali stable inulin. J Clin Invest. 1955;34:1520–1523
  20. Finney H, Newman DJ, Gruber W, Merle P, Price CP. Initial evaluation of cystatin C measurement by particle-enhanced inmunonephelometry on Behring nephelometer system. Clin Chem. 1997;43:1016–1022
  21. Bang LE, Holm J, Svendsen TL. Retinol binding protein and transferring in urine (New markers of renal function in essential hypertension and white coat hypertension?). Am J Hypertens. 1996;9:1024–1028
  22. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502
  23. Causse E, Issac P, Malatray P, et al. Assays for total homocysteine and other thiols by capillary electrophoresis-laser-induced fluorescence detection (I. Preanalytical conditions studies). J Chromatogr A. 2000;895:173–178
  24. Chu X-Y, Bleasby K, Yabut J, et al. Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4c1, and multidrug resistance p-glycoprotein. J Pharmacol Exp Ther. 2007;321:673–683
  25. Macisaac RJ, Tsalamandris C, Thomas MC, et al. The accuracy of cystatin C and commonly used creatinine-based methods for detecting moderate and mild chronic kidney disease in diabetes. Diabet Med. 2007;24:443–448
  26. Filler G, Bokenkamp A, Hoffman W, Le Bricon T, Martinez-Bru C, Grubb A. Cystatin C as a marker of GFR—History, indications, and future research. Clin Biochem. 2005;38:1–8
  27. Westphal S, Dierkes J, Luley C. Effects of fenofibrate and gemfibrozil on plasma homocysteine. Lancet. 2001;358:39–40
  28. Abrahamson M, Olafsson I, Palsdottir A, et al. Structure and expression of the human cystatin C gene. Biochem J. 1990;268:287–294
  29. Trof RJ, Di Maggio F, Leemreis J, Groeneveld AB. Biomarkers of acute renal injury and renal failure. Shock. 2006;26:245–253
  30. Herget-Rosenthal S, van Wijk JA, Bröcker-Preuss M, Bökenkamp A. Increased urinary cystatin C reflects structural and functional renal tubular impairment independent of glomerular filtration rate. Clin Biochem. 2007;40:946–951
  31. Liamis G, Bairaktari ET, Elisaf MS. Effect of fenofibrate on serum uric acid levels. Am J Kidney Dis. 1999;34:594–595
  32. Luc G, Jacob N, Bouly M, Fruchart JC, Staels B, Giral P. Fenofibrate increases homocystinemia through a PPARα-mediated mechanism. J Cardiovasc Pharmacol. 2004;43:452–453
  33. Genest J, Frohlich J, Steiner G. Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus. Am J Cardiol. 2004;93:848–853
  34. Drury P FIELD Investigators. Mild renal impairment and cardiovascular outcomes in type 2 diabetes: Results from the FIELD Study. Diabetologia. 2006;49(suppl 1):S6–S7

 Originally published online as doi:10.1053/j.ajkd.2008.01.014 on March 28, 2008.

PII: S0272-6386(08)00121-2

doi: 10.1053/j.ajkd.2008.01.014

American Journal of Kidney Diseases
Volume 51, Issue 6 , Pages 904-913 , June 2008

Article Tools

* Image Usage & Resolution